MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer

Valesca Pavlawna Retèl, Laura J. van ‘t Veer, F. Cardoso, M.J. Piccart, Emiel J.Th. Rutgers, K. Tryfonidis, C. Poncet, Willem H. van Harten

Research output: Contribution to journalMeeting AbstractAcademic

Fingerprint

Dive into the research topics of 'MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences